Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
A phase 1/2 trial of A novel hGIIA-Vimentin Inhibitor in prostate cancer, ovarian cancer, glioma & glioblastoma, pancreatic ductal adenocarcinoma and skin cancer, run by Filamon LTD, now recruiting.
Overview
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours is a phase 1/2 interventional study registered as NCT06926075 by Filamon LTD, with 80 participants planned, started 2025-11-07 and due to reach its primary completion in 2027-10-26. Interventions recorded: A novel hGIIA-Vimentin Inhibitor and Dose expansion.
Similar pages
not linked directly; found by shared links- TrialA Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
- TrialPhase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialSafety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
- TrialStudy of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialPsilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.